Myelofibrosis can present itself as a primary disease, which means the first presentation of a disease in patients, or can be a progression of diseases such as polycythemia vera, essential ...

Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. ... (ET) or myelofibrosis.

The myeloproliferative disorders, comprising polycythemia vera, essential thrombocytosis, and myelofibrosis, are clonal hematopoietic cancers that have an indolent course. The clinical manifestatio ...

Shouldering the Weight of Myelofibrosis —A recent survey catalogs the worries of patients with this rare form of chronic leukemia—from delays in diagnosis, to stressors involved in finding ...

Myelofibrosis, with an incidence of 1.46 per 100,000 population, 1 comprises a subset of conditions including primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post ...

Collectively for these 3 diseases—conditions that I repeat mentioning, essential thrombocythemia, polycythemia vera, myelofibrosis, and maybe we should also mention the prefibrotic myelofibrosis ...

Polycythemia vera and primary myelofibrosis share a propensity to progress toward a myelofibrotic late stage with overlapping clinical characteristics. Bone marrow features potentially useful for ...

This live webcast will provide the latest insights on five patient cases with polycythemia vera (PV) or myelofibrosis (MF). February 11, 2019 01:51 PM Eastern Standard Time ...

The FDA based its decision on data from the double-blind, randomized, placebo-controlled phase 3 JAKARTA trial — a pivotal study designed to evaluate the efficacy of once-daily doses of Inrebic ...

The FDA first approved Jakafi as a treatment for patients with intermediate and high-risk myelofibrosis in late 2011. This approval included the treatment of primary myelofibrosis, post-polycythemia ...

Ruxolitinib has become the first drug for polycythemia vera to be approved by the FDA; the drug is already marketed for use in myelofibrosis, another bone marrow disorder.

Additionally, 40% of Inrebic-treated patients (N=89) demonstrated a ≥50% improvement in Total Symptom Score (secondary end point), as measured by the modified Myelofibrosis Symptom Assessment ...